Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

This retrospective study from a tertiary care center in North India examined outcomes of high-risk multiple myeloma (HRMM) patients, finding that autologous stem cell transplant (ASCT) significantly improved overall survival (OS) and progression-free survival (PFS) rates. Patients who received ASCT had a 3-year OS of 74.7% compared to 52.9% without ASCT, highlighting the benefit of aggressive treatment in real-world settings for HRMM.